<div class="tables frame-topbot rowsep-0 colsep-0" id="tbl3">
<div class="captions"><span id="cecap80"><p id="spara150"><span class="label">Table 3</span>. Efficacy of ezetimibe on the primary composite endpoint stratified by baseline polyvascular disease and type 2 diabetes</p></span></div>
<div class="groups"><table>
<thead><tr class="valign-top rowsep-1">
<th scope="col"></th>
<th scope="col" class="align-left"><strong>Simvastatin and placebo</strong></th>
<th scope="col" class="align-left"><strong>Simvastatin and ezetimibe</strong></th>
<th scope="col" class="align-left"><strong>Absolute risk reduction (95% CI)</strong></th>
<th scope="col" class="align-left"><strong>HR (95% CI)</strong></th>
<th scope="col" class="align-left"><strong>p<sub>interaction</sub></strong></th>
</tr></thead>
<tbody>
<tr class="valign-top">
<td class="align-left">No polyvascular disease<a name="btbl3fn1" href="#tbl3fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">2337 (33·0%)</td>
<td class="align-left">2207 (31·3%)</td>
<td class="align-left">1·7% (0·33 to 3·04)</td>
<td class="align-left">0·94 (0·89–1·00)</td>
<td class="align-left">0·75</td>
</tr>
<tr class="valign-top">
<td class="align-left">Polyvascular disease<a name="btbl3fn1" href="#tbl3fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">403 (49·5%)</td>
<td class="align-left">365 (45·2%)</td>
<td class="align-left">4·2% (−1·06 to 9·53)</td>
<td class="align-left">0·92 (0·80–1·06)</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-top">
<td class="align-left">Polyvascular disease<a name="btbl3fn1" href="#tbl3fn1" class="workspace-trigger"><sup>*</sup></a> without type 2 diabetes</td>
<td class="align-left">219 (41·3%)</td>
<td class="align-left">186 (38·2%)</td>
<td class="align-left">3·1% (−3·4 to 9·6)</td>
<td class="align-left">0·89 (0·73–1·08)</td>
<td class="align-left">0·90</td>
</tr>
<tr class="valign-top">
<td class="align-left">Polyvascular disease with<a name="btbl3fn1" href="#tbl3fn1" class="workspace-trigger"><sup>*</sup></a> type 2 diabetes</td>
<td class="align-left">184 (65·1%)</td>
<td class="align-left">179 (56·0%)</td>
<td class="align-left">9·1% (−0·1 to 18·3)</td>
<td class="align-left">0·91 (0·74–1·11)</td>
<td class="align-left">..</td>
</tr>
</tbody>
</table></div>
<p class="legend"></p>
<p id="spara160">Data
 are n (Kaplan-Meier %). Primary composite endpoint consisted of 
cardiovascular death, a major coronary event (ie, a non-fatal myocardial
 infarction, documented unstable angina requiring hospital admission, or
 coronary revascularisation occurring at least 30 days after 
randomisation), or stroke (ischaemic or haemorrhagic). HR=hazard ratio.</p>
<dl class="footnotes">
<dt id="tbl3fn1">*</dt>
<dd><p id="cenpara60">Polyvascular disease defined as concomitant known peripheral artery disease, stroke or transient ischaemic attack, or both.</p></dd>
</dl>
</div>
